Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Inovio Pharmaceuticals, Inc. (INO) is a Biotechnology company based in US with a market capitalization of $58.9M. Revenue declined 70.0% year-over-year and free cash flow was negative at -$88.9M. This page tracks INO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 134 employees · IPO Dec 8, 1998

Valuation

Valuation & price

$1.30as of May 17, 2026· -54.7% vs 52w high

P/E ratio

Latest-FY diluted EPS

2.45

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$2.79$1.88$0.97Jul 25Jan 26Jul 26
$0.9752-week range$2.87
Loading valuation history…

Fundamentals

Key fundamentals

$58.9M

Market cap

-70.0%

Revenue growth (YoY)

100.0%

Gross margin

-$88.9M

Free cash flow (USD)

-$49.1M

Net debt

Net cash position

1626.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$35.4M$65.3K

Free cash flow by year

20162025

-$66.5M-$88.9M

Gross margin by year

20212025

100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • FinancingJul 2, 2026Filing

    Securities Registration

  • 8-K eventMay 20, 2026Filing

    Bylaws Amendment

  • Quarterly reportMay 13, 2026Filing

    10-Q Filed

  • 8-K eventMay 13, 2026Filing

    Earnings Release

  • 8-K eventApr 6, 2026Filing

    Public Offering Announced

  • 8-K eventApr 2, 2026Filing

    ATM Prospectus Termination

Questions

Frequently asked questions

What is Inovio Pharmaceuticals, Inc.'s market cap?

Inovio Pharmaceuticals, Inc. (INO) has a market capitalization of $58.9M.

What is INO's P/E ratio?

A meaningful P/E ratio is not available for INO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is INO's price-to-book (P/B) ratio?

INO trades at 2.45 times book value per share.

Are insiders buying INO stock?

SEC Form 4 filings show no open-market insider buys at Inovio Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.